BACKGROUND: The cause of historically higher rates of invasive pneumococcal disease among blacks than whites has remained unknown. We tested the hypothesis that sickle cell trait or hemoglobin C trait is an independent risk factor for invasive pneumococcal disease. METHOD: Eligible children were born in Tennessee (1996-2003), had a newborn screen, enrolled in TennCare aged <1 year, and resided in a Tennessee county with laboratory-confirmed, pneumococcal surveillance. Race/ethnicity was ascertained from birth certificates. Children were followed through 2005 until loss of enrollment, pneumococcal disease episode, fifth birthday, or death. We calculated incidence rates by race/ethnicity and hemoglobin type before and after pneumococcal conjugate vaccine (PCV7) introduction. Poisson regression analyses compared invasive pneumococcal disease rates among blacks with sickle cell trait or hemoglobin C trait with whites and blacks with normal hemoglobin, controlling for age, gender, time (pre-PCV7, transition year, or post-PCV7) and high-risk conditions (eg, heart disease). RESULTS: Over 10 years, 415 invasive pneumococcal disease episodes occurred during 451,594 observed child-years. Before PCV7 introduction, disease rates/100,000 child-years were 2941 for blacks with sickle cell disease, 258 for blacks with sickle cell trait or hemoglobin C trait and 188, 172, and 125 for blacks, whites, and Hispanics with normal hemoglobin. Post-PCV7, rates declined for all groups. Blacks with sickle cell trait or hemoglobin C trait had 77% (95% CI = 22-155) and 42% (95% CI = 1-100) higher rates than whites and blacks with normal hemoglobin. CONCLUSION: Black children with sickle cell trait or hemoglobin C trait have an increased risk of invasive pneumococcal disease.
BACKGROUND: The cause of historically higher rates of invasive pneumococcal disease among blacks than whites has remained unknown. We tested the hypothesis that sickle cell trait or hemoglobin C trait is an independent risk factor for invasive pneumococcal disease. METHOD: Eligible children were born in Tennessee (1996-2003), had a newborn screen, enrolled in TennCare aged <1 year, and resided in a Tennessee county with laboratory-confirmed, pneumococcal surveillance. Race/ethnicity was ascertained from birth certificates. Children were followed through 2005 until loss of enrollment, pneumococcal disease episode, fifth birthday, or death. We calculated incidence rates by race/ethnicity and hemoglobin type before and after pneumococcal conjugate vaccine (PCV7) introduction. Poisson regression analyses compared invasive pneumococcal disease rates among blacks with sickle cell trait or hemoglobin C trait with whites and blacks with normal hemoglobin, controlling for age, gender, time (pre-PCV7, transition year, or post-PCV7) and high-risk conditions (eg, heart disease). RESULTS: Over 10 years, 415 invasive pneumococcal disease episodes occurred during 451,594 observed child-years. Before PCV7 introduction, disease rates/100,000 child-years were 2941 for blacks with sickle cell disease, 258 for blacks with sickle cell trait or hemoglobin C trait and 188, 172, and 125 for blacks, whites, and Hispanics with normal hemoglobin. Post-PCV7, rates declined for all groups. Blacks with sickle cell trait or hemoglobin C trait had 77% (95% CI = 22-155) and 42% (95% CI = 1-100) higher rates than whites and blacks with normal hemoglobin. CONCLUSION: Black children with sickle cell trait or hemoglobin C trait have an increased risk of invasive pneumococcal disease.
Authors: D Modiano; G Luoni; B S Sirima; J Simporé; F Verra; A Konaté; E Rastrelli; A Olivieri; C Calissano; G M Paganotti; L D'Urbano; I Sanou; A Sawadogo; G Modiano; M Coluzzi Journal: Nature Date: 2001-11-15 Impact factor: 49.962
Authors: Natasha B Halasa; Sadhna M Shankar; Thomas R Talbot; Patrick G Arbogast; Ed F Mitchel; Winfred C Wang; William Schaffner; Allen S Craig; Marie R Griffin Journal: Clin Infect Dis Date: 2007-04-18 Impact factor: 9.079
Authors: A Schuchat; T Hilger; E Zell; M M Farley; A Reingold; L Harrison; L Lefkowitz; R Danila; K Stefonek; N Barrett; D Morse; R Pinner Journal: Emerg Infect Dis Date: 2001 Jan-Feb Impact factor: 6.883
Authors: Thomas N Williams; Tabitha W Mwangi; David J Roberts; Neal D Alexander; David J Weatherall; Sammy Wambua; Moses Kortok; Robert W Snow; Kevin Marsh Journal: PLoS Med Date: 2005-05-31 Impact factor: 11.069
Authors: Jonathan C Goldsmith; Vence L Bonham; Clinton H Joiner; Gregory J Kato; Allan S Noonan; Martin H Steinberg Journal: Am J Hematol Date: 2012-02-03 Impact factor: 10.047
Authors: Amanda B Payne; Ruth Link-Gelles; Ijeoma Azonobi; W Craig Hooper; Bernard W Beall; James H Jorgensen; Billie Juni; Matthew Moore Journal: Pediatr Infect Dis J Date: 2013-12 Impact factor: 2.129
Authors: J Anthony G Scott; James A Berkley; Isaiah Mwangi; Lucy Ochola; Sophie Uyoga; Alexander Macharia; Carolyne Ndila; Brett S Lowe; Salim Mwarumba; Evasius Bauni; Kevin Marsh; Thomas N Williams Journal: Lancet Date: 2011-09-06 Impact factor: 79.321
Authors: Steven M Szczepanek; Sean Roberts; Kara Rogers; Christina Cotte; Alexander J Adami; Sonali J Bracken; Sharon Salmon; Eric R Secor; Roger S Thrall; Biree Andemariam; Dennis W Metzger Journal: PLoS One Date: 2016-02-24 Impact factor: 3.240